| pubmed-article:18019402 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18019402 | lifeskim:mentions | umls-concept:C0014644 | lld:lifeskim |
| pubmed-article:18019402 | lifeskim:mentions | umls-concept:C0015674 | lld:lifeskim |
| pubmed-article:18019402 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:18019402 | lifeskim:mentions | umls-concept:C1522577 | lld:lifeskim |
| pubmed-article:18019402 | lifeskim:mentions | umls-concept:C0249458 | lld:lifeskim |
| pubmed-article:18019402 | lifeskim:mentions | umls-concept:C0439231 | lld:lifeskim |
| pubmed-article:18019402 | lifeskim:mentions | umls-concept:C1515021 | lld:lifeskim |
| pubmed-article:18019402 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:18019402 | pubmed:dateCreated | 2007-11-16 | lld:pubmed |
| pubmed-article:18019402 | pubmed:abstractText | BACKGROUND: We hypothesized that subset classification of Epstein-Barr virus (EBV) in chronic fatigue syndrome (CFS) is required. At first, a blinded-random placebo-controlled trial of valacyclovir in EBV CFS subset was performed (Group 1), and this EBV subset was followed for thirty-six months (Group 2). Patients were given valacyclovir at 14.3 mg/kg every 6 hours. The validated Energy Index (EI) point score assessing physical functional capacity, Holter monitor, multigated (radionuclide) MUGA rest/stress ventriculographic examination, EBV serum IgM viral capsid antibodies (VCA), and EBV early antigen diffuse (EA) were followed. After six-months, Group 1 CFS patients receiving valacyclovir experienced an increased mean least square EI point score +1.12 units (122 kcal/day), while the placebo cohort increased +0.42 EI units (65 kcal/day). EI point scores at Group 2 increased progressively. Sinus tachycardias decreased and abnormal cardiac wall motion improved. Serum antibody titers to EBV VCA IgM decreased. Patients resumed normal activities. | lld:pubmed |
| pubmed-article:18019402 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18019402 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18019402 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18019402 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18019402 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18019402 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18019402 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18019402 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18019402 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18019402 | pubmed:issn | 0258-851X | lld:pubmed |
| pubmed-article:18019402 | pubmed:author | pubmed-author:FitzgeraldJam... | lld:pubmed |
| pubmed-article:18019402 | pubmed:author | pubmed-author:LernerA... | lld:pubmed |
| pubmed-article:18019402 | pubmed:author | pubmed-author:BeqajSafedin... | lld:pubmed |
| pubmed-article:18019402 | pubmed:author | pubmed-author:DeeterRobert... | lld:pubmed |
| pubmed-article:18019402 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18019402 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:18019402 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18019402 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18019402 | pubmed:pagination | 707-13 | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:meshHeading | pubmed-meshheading:18019402... | lld:pubmed |
| pubmed-article:18019402 | pubmed:articleTitle | Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up. | lld:pubmed |
| pubmed-article:18019402 | pubmed:affiliation | Department of Medicine, William Beaumont Hospital, Royal Oak, MI, USA. amartinlerner@yahoo.com | lld:pubmed |
| pubmed-article:18019402 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18019402 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:18019402 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18019402 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18019402 | lld:pubmed |
